
zzso of zzso with zzso has demonstrated zzso with zzso zzso This phase 1 study assessed the zzso zzso zzso and efficacy of zzso in combination with zzso and targeted zzso 

Advanced solid tumor patients received oral zzso 45 or 60 zzso zzso with either zzso zzso zzso and zzso 200 zzso zzso 1), zzso 75 zzso zzso zzso or zzso 100 or 150 zzso daily zzso zzso alternative schedules of zzso zzso zzso zzso or zzso zzso zzso were also zzso 

zzso of zzso zzso was 45 zzso zzso or 200 zzso zzso zzso zzso MAD was 200 zzso zzso zzso 2) and 135 zzso zzso zzso zzso zzso included skin rash zzso 1, zzso zzso zzso zzso arms 1, zzso zzso zzso arm zzso and zzso zzso arm zzso Common drug-related zzso included fatigue zzso zzso zzso and rash zzso Two patients with zzso cell zzso of the head and neck zzso 1; zzso demonstrated a complete and partial response zzso additional zzso were observed in patients (1 each) with melanoma, zzso neuroendocrine zzso zzso and cervical zzso Six patients had stable disease zzso zzso 

zzso plus zzso and zzso zzso or zzso was zzso with early evidence of zzso zzso 

